Capio Biosciences
Madison
About Capio Biosciences
Capio Biosciences is a biotech company focused on delivering high-value oncology diagnostics that can help inform patient care decisions and improve outcomes. Capio Biosciences is developing an advanced platform called CapioCyte™ for the capture of circulating tumor cells (CTCs) from whole blood. By utilizing a combination of biomimetic cell rolling and dendrimer-mediated multivalent cell capture, CapioCyte delivers significantly greater capture sensitivity than other platforms currently available. It is also able to provide enriched CTCs for post capture molecular analysis such as FISH, RNA-Seq and NGS. CapioCyte is therefore an excellent tool for today’s cancer research needs, and potentially for clinical patient management in the future.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $2.9M
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2017)
- Website: capiobiosciences.com
- Phone: 608) 441 8375
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Oncology
Social Profiles
Canonical: https://fsome.com/organization/capio-biosciences-114080 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.